Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease

Immunotherapy against amyloid-beta (Aβ) is a promising option for the treatment of Alzheimer’s disease (AD). Aβ exists as various species, including monomers, oligomers, protofibrils, and insoluble fibrils in plaques. Oligomers and protofibrils have been shown to be toxic, and removal of these aggre...

Descripción completa

Detalles Bibliográficos
Autores principales: Söderberg, Linda, Johannesson, Malin, Nygren, Patrik, Laudon, Hanna, Eriksson, Fredrik, Osswald, Gunilla, Möller, Christer, Lannfelt, Lars
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119362/
https://www.ncbi.nlm.nih.gov/pubmed/36253511
http://dx.doi.org/10.1007/s13311-022-01308-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119362/
https://www.ncbi.nlm.nih.gov/pubmed/36253511
http://dx.doi.org/10.1007/s13311-022-01308-6

Ejemplares similares